Risultati di ricerca
‘The Bottom Of It’ is a podcast hosted by New Zealander Joshua Moriarty who is a musician, songwriter and performer for both Miami Horror & All The Colours. These candid conversations philosophise and muse over the music industry, the meaning of life, what art offers to the world, what being a creative gives back to the people of this planet and how to try and keep yourself sane in a world ...
Joshua Moriarty. Melbourne, Australia. ‘Pointlessness is the ultimate freedom. It views life as a blank canvas to paint with whatever shapes, colours and brushes you wish.
CEO | Board Member | Consultant Ophthalmology and Orthopedics | Learn more about Joshua Moriarty’s work experience, education, connections & more by visiting their profile on LinkedIn
- Okogen, Inc.
8 mar 2022 · Lead candidate, OKG-0502, to address significant unmet medical need. San Diego, CA and Melbourne, AUS – March 8, 2022 – Okogen, an ophthalmic biotechnology company, today announced the appointment of Joshua Moriarty as the new Chief Executive Officer (CEO). Mr. Moriarty will immediately commence the role previously held by Co-Founder Brian Strem, PhD (CEO at Kiora Pharmaceuticals […]
Although it's not exactly new Miami Horror as such, the band's guitarist Joshua Moriarty has just announced his own side-project, which launched with its debut single R.T.F.L. . R.T.F.L. is a really lush and hypnotic release, distancing itself from the upbeat, disco-infused sound of Miami Horror in favour of a more relaxed and low-key electro ...
8 mar 2022 · Okogen, an ophthalmic biotechnology company, today announced the appointment of Joshua Moriarty as the new Chief Executive Officer (CEO). With 17 years in ophthalmic product development, Joshua Moriarty will lead Okogen and the further development of OKG-0502 following positive results and clear direction forward from the interim analysis of the RUBY Trial.
8 mar 2022 · Okogen, an ophthalmic biotechnology company, today announced the appointment of Joshua Moriarty as the new Chief Executive Officer (CEO). With 17 years in ophthalmic product development, Joshua Moriarty will lead Okogen and the further development of OKG-0502 following positive results and clear direction forward from the interim analysis of the RUBY Trial.
